Business Description
Eupraxia Pharmaceuticals Inc
NAICS : 541714
SIC : 3741
Compare
Compare
Traded in other countries / regions
EPRX.CanadaEPRXF.USA IPO Date
2021-03-09Description
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.72 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 1.5 | |||||
| Debt-to-EBITDA | -0.55 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -38.4 | |||||
| 3-Year EPS without NRI Growth Rate | -30.5 | |||||
| 3-Year FCF Growth Rate | -34.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 29.42 | |||||
| 9-Day RSI | 34.99 | |||||
| 14-Day RSI | 39.84 | |||||
| 6-1 Month Momentum % | 77.78 | |||||
| 12-1 Month Momentum % | 236.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.35 | |||||
| Quick Ratio | 1.35 | |||||
| Cash Ratio | 1.31 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -18.8 | |||||
| Shareholder Yield % | -0.47 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -130.5 | |||||
| ROA % | -74.28 | |||||
| ROIC % | -571.25 | |||||
| ROC (Joel Greenblatt) % | -3100.46 | |||||
| ROCE % | -90.66 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 23 | |||||
| Price-to-Tangible-Book | 23.23 | |||||
| EV-to-EBIT | -9.18 | |||||
| EV-to-EBITDA | -9.25 | |||||
| EV-to-FCF | -9.83 | |||||
| Price-to-Net-Current-Asset-Value | 24.83 | |||||
| Price-to-Net-Cash | 27.69 | |||||
| Earnings Yield (Greenblatt) % | -10.89 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eupraxia Pharmaceuticals Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil C$) | |||
| EPS (TTM) (C$) | -1.04 | ||
| Beta | 0 | ||
| Volatility % | 91.73 | ||
| 14-Day RSI | 39.84 | ||
| 14-Day ATR (C$) | 0.319033 | ||
| 20-Day SMA (C$) | 7.698 | ||
| 12-1 Month Momentum % | 236.45 | ||
| 52-Week Range (C$) | 2 - 9.1 | ||
| Shares Outstanding (Mil) | 27.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eupraxia Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eupraxia Pharmaceuticals Inc Stock Events
| Event | Date | Price(C$) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eupraxia Pharmaceuticals Inc Frequently Asked Questions
What is Eupraxia Pharmaceuticals Inc(TSX:EPRX)'s stock price today?
The current price of TSX:EPRX is C$7.20. The 52 week high of TSX:EPRX is C$9.10 and 52 week low is C$2.00.
When is next earnings date of Eupraxia Pharmaceuticals Inc(TSX:EPRX)?
The next earnings date of Eupraxia Pharmaceuticals Inc(TSX:EPRX) is .
Does Eupraxia Pharmaceuticals Inc(TSX:EPRX) pay dividends? If so, how much?
Eupraxia Pharmaceuticals Inc(TSX:EPRX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers